

The invention relates to medicine, in particular to hepatology, and can be used for the treatment of chronic viral hepatitis C.

According to the invention, the claimed method consists in that it is administered the basic therapy and additionally, is concomitantly administered *per os* 5 α -furostan-3 β ,22,26-triol-3-[O- β -D-glucopyranosyl (1 \rightarrow 2)- β -D-glucopyranosyl(1 \rightarrow 4)- β -D-galactopyranosyl]-26-O- β -D-glucopyranosyl, twice a day, and 3-O-[β -D-glucopyranosyl(1 \rightarrow 2)]-[β -D-glu-copyranosyl(1 \rightarrow 3)]-[β -D-glucopyranosyl (1 \rightarrow 4)- β -D-galactopyranosyl[(25R)-5 α -furostan-2 α , 3 β , 22 α , 26-tetraol]-26-O- β -D-glucopyranosyl, once a day, both remedies are administered in a dose of 50 mg, beginning with the first day of clinical manifestations, 30 minutes before meal, during 3 months.

Claims: 1